Iscador adjuvant to chemotherapy was reported to decrease therapy-related adverse drug reactions, to increase response rates and to improve disease symptom control, quality of life and overall survival [ 15, 18, 44, 45].
Symptoms such as CINV are a major cause of reduced quality of life in chemotherapy patients and lead to decreased therapy compliance.
The number of B lines did decrease with therapy, but did not reach statistical significance likely because the sampled population was small and had only mild heart failure.
Furthermore expression of IL-1β in the synovial tissue remained unchanged, while IL-6 tended to decrease after therapy.
The Vd may decrease during therapy when capillary leakage subsides and sepsis resolves [ 48].
The viral effective population of those patients also showed a strong decrease after therapy.
The effective population of those patients also showed a strong decrease after therapy.
These results were not significantly different, and the titer tended to decrease after therapy.
In order to decrease the therapy associated toxicities smaller irradiation volumes used with 3D conformal techniques might be better.
In contrast, gesture showed a numerical decrease (pre-therapy mean = 7.5, post-therapy mean = 5.2) and writing remained relatively stable (pre-therapy mean = 1.7, post-therapy mean = 1.3).
In ileal Crohn's disease (CD), expression of two neuropeptides with antimicrobial activity, PYY and CHGB, was significantly decreased before therapy compared to control ileums, and ileal PYY expression remained significantly decreased after therapy in CD responders.
